Cristiana T. Trinconi
Tamoxifen inhibits the biosynthesis of inositolphosphorylceramide in Leishmania
Trinconi, Cristiana T.; Miguel, Danilo C.; Silber, Ariel M.; Brown, Christopher; Mina, John G.M.; Denny, Paul W.; Heise, Norton; Uliana, Silvia R.B.
Authors
Danilo C. Miguel
Ariel M. Silber
Christopher Brown
John G.M. Mina
Professor Paul Denny p.w.denny@durham.ac.uk
Professor
Norton Heise
Silvia R.B. Uliana
Abstract
Previous work from our group showed that tamoxifen, an oral drug that has been in use for the treatment of breast cancer for over 40 years, is active both in vitro and in vivo against several species of Leishmania, the etiological agent of leishmaniasis. Using a combination of metabolic labeling with [3H]-sphingosine and myo-[3H]-inositol, alkaline hydrolysis, HPTLC fractionations and mass spectrometry analyses, we observed a perturbation in the metabolism of inositolphosphorylceramides (IPCs) and phosphatidylinositols (PIs) after treatment of L. amazonensis promastigotes with tamoxifen, with a significant reduction in the biosynthesis of the major IPCs (composed of d16:1/18:0-IPC, t16:0/C18:0-IPC, d18:1/18:0-IPC and t16:0/20:0-IPC) and PIs (sn-1-O-(C18:0)alkyl -2-O-(C18:1)acylglycerol-3-HPO4-inositol and sn-1-O-(C18:0)acyl-2-O-(C18:1)acylglycerol-3-HPO4-inositol) species. Substrate saturation kinetics of myo-inositol uptake analyses indicated that inhibition of inositol transport or availability were not the main reasons for the reduced biosynthesis of IPC and PI observed in tamoxifen treated parasites. An in vitro enzymatic assay was used to show that tamoxifen was able to inhibit the Leishmania IPC synthase with an IC50 value of 8.48 μM (95% CI 7.68–9.37), suggesting that this enzyme is most likely one of the targets for this compound in the parasites.
Citation
Trinconi, C. T., Miguel, D. C., Silber, A. M., Brown, C., Mina, J. G., Denny, P. W., …Uliana, S. R. (2018). Tamoxifen inhibits the biosynthesis of inositolphosphorylceramide in Leishmania. International Journal for Parasitology: Drugs and Drug Resistance, 8(3), 475-487. https://doi.org/10.1016/j.ijpddr.2018.10.007
Journal Article Type | Article |
---|---|
Acceptance Date | Oct 23, 2018 |
Online Publication Date | Oct 24, 2018 |
Publication Date | Dec 1, 2018 |
Deposit Date | Oct 26, 2018 |
Publicly Available Date | Nov 12, 2018 |
Journal | International Journal for Parasitology: Drugs and Drug Resistance |
Print ISSN | 2211-3207 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 8 |
Issue | 3 |
Pages | 475-487 |
DOI | https://doi.org/10.1016/j.ijpddr.2018.10.007 |
Public URL | https://durham-repository.worktribe.com/output/1344248 |
Files
Published Journal Article
(2.5 Mb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by-nc-nd/4.0/
Copyright Statement
© 2018 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
You might also like
Rapid genotyping of Toxoplasma gondii isolates via Nanopore-based multi-locus sequencing
(2024)
Journal Article
TREATMENT OF LEISHMANIASIS
(2024)
Patent
Clemastine/tamoxifen hybrids as easily accessible antileishmanial drug leads
(2024)
Journal Article
Downloadable Citations
About Durham Research Online (DRO)
Administrator e-mail: dro.admin@durham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search